Targeted Therapies in Oncology
February I, 2024
Volume: 13
Issue: 2
January I, 2024
Volume: 13
Issue: 1
December II, 2023
Volume: 12
Issue: 18
December I, 2023
Volume: 12
Issue: 17
November II, 2023
Volume: 12
Issue: 16
November I, 2023
Volume: 12
Issue: 15
October II, 2023
Volume: 12
Issue: 14
October I
Volume: 12
Issue: 13
September I
Volume: 12
Issue: 12
August I
Volume: 12
Issue: 11
July 1, 2023
Volume: 12
Issue: 9
July II, 2023
Volume: 12
Issue: 10
June 2023
Volume: 12
Issue: 8
May 2023
Volume: 12
Issue: 7
April 2, 2023
Volume: 12
Issue: 6
April 1, 2023
Volume: 12
Issue: 5
March 1, 2023
Volume: 12
Issue: 3
February 2023
Volume: 12
Issue: 2
January 2023
Volume: 11
Issue: 17
December 2, 2022
Volume: 11
Issue: 18
December 1, 2022
Volume: 11
Issue: 17
November 2, 2022
Volume: 11
Issue: 16
November 1, 2022
Volume: 11
Issue: 15
October 1, 2022
October 2, 2022
Volume: 11
Issue: 14
September 2022
Volume: 11
Issue: 12
August 2022
Volume: 11
Issue: 11
July 1, 2022
Volume: 11
Issue: 9
July 2, 2022
Volume: 11
Issue: 10
June 1, 2022
Volume: 11
Issue: 8
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
Phase 3 Data Highlight Orca-T’s Clinical Benefits in Heme Malignancies
5